Ovature | A research opportunity for women with recurrent ovarian cancer

A new clinical research study called OVATURE (OVArian TUmor REsponse) is underway in the U.S., Europe and Australia. Patients in the trial will receive an experimental treatment regimen consisting of weekly carboplatin. Half of the patients in the trial will also receive the investigational drug phenoxodiol. The other half will receive a placebo so that neither researchers nor patients can tell which arm of the trial the patient is in.

All patients on the trial will be receiving therapy that researchers hope may be helpful. This is because a change from an every third week to a weekly carboplatin regimen has been reported to provide tumor response in some heavily pre-treated patients with recurrent ovarian cancer.¹ In addition to learning more about the efficacy of phenoxodiol, researchers will learn more about the efficacy of weekly carboplatin.

Patients may also access more information on the OVATURE trial through www.clinicaltrials.gov (type OVATURE in the search box).

^1. M. E. van der Burg, Gaast A. van der, I. Vergote, C. W. Burger, H. C. van Doorn, Wit R. de, G. Stoter, and J. Verweij. What is the role of dose-dense therapy? Int.J.Gynecol.Cancer 15 Suppl 3:233-240, 2005.

The treatment of ovarian cancer that has become resistant to standard chemotherapy is an area of significant unmet medical need. The majority of women diagnosed with ovarian cancer eventually reach this point. Are you one of them?

Do you have ovarian cancer, fallopian tube cancer or primary peritoneal cancer?
When first treated with platinum-based chemotherapy drug (such as cisplatin or carboplatin) did you initially respond to the treatment?
Have you subsequently been treated in the past six months with a platinum-based chemotherapy drug (such as cisplatin or carboplatin), but now the cancer has progressed?

If so, you might be eligible to participate in the OVATURE clinical research study. Read more about eligibility requirements and the study here